Literature DB >> 21840933

Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation.

Dianbo Yao1, Chaoliu Dai, Songlin Peng.   

Abstract

Cancer metastasis consists of a sequential series of events, and the epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are recognized as critical events for metastasis of carcinomas. A current area of focus is the histopathological similarity between primary and metastatic tumors, and MET at sites of metastases has been postulated to be part of the process of metastatic tumor formation. Here, we summarize accumulating evidence from experimental studies that directly supports the role of MET in cancer metastasis, and we analyze the main mechanisms that regulate MET or reverse EMT in carcinomas. Given the critical role of MET in metastatic tumor formation, the potential to effectively target the MET process at sites of metastasis offers new hope for inhibiting metastatic tumor formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840933     DOI: 10.1158/1541-7786.MCR-10-0568

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  149 in total

Review 1.  Tumor-derived exosomes in oncogenic reprogramming and cancer progression.

Authors:  Sarmad N Saleem; Asim B Abdel-Mageed
Journal:  Cell Mol Life Sci       Date:  2014-08-26       Impact factor: 9.261

2.  MicroRNA-92a functions as an oncogene in colorectal cancer by targeting PTEN.

Authors:  Guangjun Zhang; He Zhou; Huaxu Xiao; Zuoliang Liu; Hongpeng Tian; Tong Zhou
Journal:  Dig Dis Sci       Date:  2013-09-12       Impact factor: 3.199

3.  Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.

Authors:  Gerhard Hamilton; Maximilian Hochmair; Barbara Rath; Lukas Klameth; Robert Zeillinger
Journal:  Cell Adh Migr       Date:  2016-02-26       Impact factor: 3.405

4.  Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.

Authors:  J C Evans; J McCarthy; C Torres-Fuentes; J F Cryan; J Ogier; R Darcy; R W Watson; C M O'Driscoll
Journal:  Gene Ther       Date:  2015-05-25       Impact factor: 5.250

Review 5.  Molecular alterations that drive breast cancer metastasis to bone.

Authors:  Penelope D Ottewell; Liam O'Donnell; Ingunn Holen
Journal:  Bonekey Rep       Date:  2015-03-18

Review 6.  Cell signalling pathways underlying induced pluripotent stem cell reprogramming.

Authors:  Kate Hawkins; Shona Joy; Tristan McKay
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

7.  Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients.

Authors:  Waleed Kian; Laila C Roisman; Nir Peled
Journal:  Transl Lung Cancer Res       Date:  2018-12

8.  MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma.

Authors:  Feng Liu; Linfeng Wu; Anping Wang; Yajun Xu; Xiaodong Luo; Xing Liu; Yi Hua; Deying Zhang; Shengde Wu; Tao Lin; Dawei He; Guanghui Wei; Shanwen Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

9.  Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.

Authors:  Yingming Zhu; Yuanwei Zang; Fen Zhao; Zhenxiang Li; Jianbo Zhang; Liang Fang; Minghuan Li; Ligang Xing; Zhonghua Xu; Jinming Yu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

10.  SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis.

Authors:  Petra Simic; Eric O Williams; Eric L Bell; Jing Jing Gong; Michael Bonkowski; Leonard Guarente
Journal:  Cell Rep       Date:  2013-04-11       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.